Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study

<p>This study aimed to investigate the effectiveness and safety of Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) in the real world. All consecutive patients with RA from the KEIO-RA cohort who had received a JAKi from July 2013 to June 2023 were included. We assess...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Satoshi Takanashi (15221350) (author)
مؤلفون آخرون:	Masatoshi Kawai (2074750) (author), Mitsuhiro Akiyama (3412106) (author), Yasushi Kondo (371654) (author), Shuntaro Saito (4519816) (author), Masaru Takeshita (6197132) (author), Jun Kikuchi (266172) (author), Hironari Hanaoka (3910738) (author), Yuko Kaneko (839653) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Pharmacology Biotechnology Ecology Immunology Developmental Biology Science Policy Chemical Sciences not elsewhere classified Rheumatoid arthritis JAK inhibitors difficult-to-treat rheumatoid arthritis retention rates effectiveness safety
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study

مواد مشابهة